An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

Part of paid clinical trials in Maitland, Florida.

Sponsor
Voyager Therapeutics
Study ID
NCT07764146
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Alzheimer s Disease

Eligibility Criteria

Sex
ALL
Age
30 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • VY1706 Low dose — DRUG
    Low dose
  • VY1706 Mid dose — DRUG
    Mid Dose
  • VY1706 High Dose — DRUG
    High dose
  • Anti-AAV9 Total Antibody (TAb) Assay — DEVICE
    Anti-AAV9 Total Antibody (TAb) Assay

Study Details

VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study

Key Dates

First listed
Aug 13, 2026
Start date
Sep 3, 2026
Status verified
Sep 2026
Primary completion
Apr 28, 2029
Completion
Apr 28, 2029

Study Design

Enrollment
18 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Low dose IV Infusion
  • Experimental: Mid dose IV Infusion
  • Experimental: High dose IV Infusion

Primary Outcome Measure

To characterize the safety and tolerability in participants with AD by Incidence of treatment emergent adverse events, changes from baseline in vital signs, physical and neurological exams and other safety measures [ Time Frame: 52 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
K2 Medical Research, LLCMaitlandFlorida32751
Recruitment Coordinator
407-676-5252

Find similar trials in Maitland, FL

By research site
K2 Medical Research, LLC· Maitland, FL

Related Studies